~~<i id='995BCE2C35'><strike id='995BCE2C35'><tt id='995BCE2C35'><pre id='995BCE2C35'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：fashion 2025-08-12 08:28:28 - browse：76139

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Merck CEO won’t testify in Senate, citing no expertise in drug prices

leisure time

focus

entertainment

knowledge

hotspot

Wikipedia

PhotosfromSTAT'sfirstyearofpublishinglaidoutforanedit.AlissaAmbrose/STATTodaySTATturns8.Intheseannua

WSS

Senate panel clears PBM, hopsital reforms

Excited delirium, Elijah McClain, and emergency physicians

Abortion clinic in Cancun will cater to Americans

STAT Executive Editor Rick Berke on STAT's 8th birthday

How generative AI ratchets up security threats for health systems

The Affordable Care Act has saved billions in health care costs

knowledge

focus

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why you shouldn’t ask, “What country has the best health care?”

Walensky prepares to leave CDC — and Congress — behind

UCSF medical school apologizes for unethical prisoner experiments

In Memoriam: Notable people who died in 2023

Merck, Johnson & Johnson CEOs will testify on high drug prices

Activists slam private health insurers over coverage restrictions

STAT Executive Editor Rick Berke on STAT's 8th birthday

Sports medicine is finally prioritizing gender equality

Diversify hospital leadership teams to protect BIPOC patient health

focus

FDA approves Recor Medical high blood pressure device

Bernie Sanders is gearing up to subpoena pharma CEOs

Health Care Service Corp to buy Cigna Medicare Advantage plans

Free speech concerns arise in wake of journal editor Eisen's firing

Investment in vaccine development is lagging, report finds

Medicare Advantage insurers face 0.2% cut to 2025 payments

entertainment

knowledge

hotspot

Wikipedia